Claims for Patent: 10,751,305

Summary for Patent: 10,751,305

Title:	Solid-forming topical formulations for pain control
Abstract:	Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.
Inventor(s):	Zhang; Jie (Salt Lake City, UT), Hull; Wade (Kaysville, UT), Vo; Ngoc Truc-Chi (Longueuil, CA)
Assignee:	Crescita Therapeutics Inc. (Mississauga, CA)
Application Number:	15/655,595
Patent Claims:	1. A solid-forming topical formulation comprising: from about 4 wt % to about 10 wt % lidocaine; from about 4 wt % to about 10 wt % tetracaine; from about 2 wt % to about 6 wt % of sorbitan monopalmitate or sorbitan monostearate; from about 18 wt % to about 32.4 wt % dicalcium phosphate; from about 10 wt % to about 18 wt % polyvinyl alcohol; from about 2 wt % to about 13 wt % petrolatum; and from about 29.54 wt % to about 50 wt % water; wherein a water to polyvinyl alcohol weight ratio (w/w) is at least 2.4. 2. The formulation of claim 1, wherein the sorbitan monostearate is present and the formulation further includes sorbitan monooleate. 3. The formulation of claim 1, wherein the formulation comprises 7 wt % lidocaine, 7 wt % tetracaine, 12 wt % polyvinyl alcohol, 10 wt % white petrolatum, and 2 wt % sorbitan monopalmitate. 4. The formulation of claim 1, wherein an amount of the dicalcium phosphate in the formulation ranges from about 25 wt % to about 32.4 wt %. 5. A solid-forming topical formulation comprising: from about 4 wt % to about 10 wt % lidocaine; from about 4 wt % to about 10 wt % tetracaine; from about 2 wt % to about 6 wt % of sorbitan monopalmitate or sorbitan monostearate; from about 18 wt % to about 35 wt % dicalcium phosphate; from about 2 wt % to about 13 wt % petrolatum; up to 50 wt % water; and from about 10 wt % to about 18 wt % polyvinyl alcohol, wherein a water to polyvinyl alcohol weight ratio (w/w) is at least 2.4. 6. The formulation of claim 5, wherein the lidocaine and the tetracaine are present in the formulation in their base forms. 7. The formulation of claim 5, wherein the lidocaine and the tetracaine are present in the formulation as a eutectic mixture. 8. The formulation of claim 5, wherein the lidocaine and the tetracaine are present in the formulation as a eutectic mixture at a 2:1 to 1:2 weight ratio. 9. The formulation of claim 5, wherein the lidocaine and the tetracaine are present are present in the formulation as a eutectic mixture at about a 1:1 weight ratio. 10. The formulation of claim 5, wherein the polyvinyl alcohol has an average mass from about 30,000 Daltons to about 80,000 Daltons. 11. The formulation of claim 5, wherein the water to polyvinyl alcohol weight ratio (w/w) ratio is greater than 2.5. 12. The formulation of claim 5, wherein an amount of the dicalcium phosphate in the formulation ranges from about 25 wt % to about 32.4 wt %. 13. The formulation of claim 5, wherein the sorbitan monostearate is present, and the formulation further includes sorbitan monooleate. 14. The formulation of claim 5, wherein the formulation comprises 7 wt % lidocaine, 7 wt % tetracaine, 12 wt % polyvinyl alcohol, 10 wt % white petrolatum, and 2.00 wt % sorbitan monopalmitate.